Brought to you by 
Bristol signs clinical trial collaboration with PsiOxus
15 Oct 2021
Executive Summary
Bristol-Myers Squibb Co. formed an alliance to test the safety, tolerability, and preliminary efficacy of a combination of its Opdivo (nivolumab) with PsiOxus Therapeutics Ltd.'s enadenotucirev in Phase I studies for multiple tumors at later stages.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol signs clinical trial collaboration with PsiOxus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice